Azitra, Inc. to Present at Biotech Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, has announced its participation in Biotech Showcase 2025. The event will take place from January 13-15, 2025 in San Francisco, with Azitra's presentation scheduled for January 13 at 3:00 p.m. PT at the Hilton San Francisco Union Square.
Chief Operating Officer Travis Whitfill will lead the presentation, and the company's management team will conduct one-on-one meetings with registered investors and potential partners. These meetings will focus on discussing Azitra's business strategy, clinical development plans, recent achievements, and future milestones.
The Biotech Showcase, organized by Demy-Colton and EBD Group, serves as a leading investor conference for private and micro-mid-cap biotechnology companies to present their innovations and connect with investors.
Azitra (NYSE American: AZTR), un'azienda biopharmaceutical in fase clinica specializzata in dermatologia di precisione, ha annunciato la sua partecipazione al Biotech Showcase 2025. L'evento si svolgerà dal 13 al 15 gennaio 2025 a San Francisco, con la presentazione di Azitra programmata per il 13 gennaio alle 15:00 PT presso l'Hilton San Francisco Union Square.
Il Chief Operating Officer Travis Whitfill condurrà la presentazione e il team di gestione dell'azienda terrà incontri individuali con investitori registrati e potenziali partner. Questi incontri si concentreranno sulla discussione della strategia aziendale di Azitra, dei piani di sviluppo clinico, dei recenti successi e delle prossime tappe future.
Il Biotech Showcase, organizzato da Demy-Colton e dal EBD Group, funge da conferenza leader per investitori dedicata a aziende biotecnologiche private e a micro e mid-cap, presentando le loro innovazioni e creando connessioni con gli investitori.
Azitra (NYSE American: AZTR), una compañía biofarmacéutica en etapa clínica especializada en dermatología de precisión, ha anunciado su participación en el Biotech Showcase 2025. El evento se llevará a cabo del 13 al 15 de enero de 2025 en San Francisco, con la presentación de Azitra programada para el 13 de enero a las 3:00 p.m. PT en el Hilton San Francisco Union Square.
El Director de Operaciones, Travis Whitfill, liderará la presentación, y el equipo de gestión de la compañía llevará a cabo reuniones uno a uno con inversores registrados y posibles socios. Estas reuniones se centrarán en discutir la estrategia empresarial de Azitra, los planes de desarrollo clínico, los logros recientes y los hitos futuros.
El Biotech Showcase, organizado por Demy-Colton y el EBD Group, sirve como una conferencia principal para inversores de compañías de biotecnología privadas y de micro y mid-cap, para presentar sus innovaciones y conectar con inversores.
Azitra (NYSE American: AZTR), 정밀 피부과에 특화된 임상 단계 생명공학 회사가 Biotech Showcase 2025에 참가한다고 발표했습니다. 이 행사는 2025년 1월 13일부터 15일까지 샌프란시스코에서 열리며, Azitra의 발표는 1월 13일 오후 3시 PT에 샌프란시스코 유니온 스퀘어 힐튼에서 진행될 예정입니다.
최고 운영 책임자 Travis Whitfill이 발표를 이끌며, 회사의 경영진팀은 등록된 투자자 및 잠재적 파트너와의 일대일 회의를 진행할 것입니다. 이러한 회의는 Azitra의 사업 전략, 임상 개발 계획, 최근 성과 및 향후 이정표를 논의하는 데 중점을 둘 것입니다.
Demy-Colton과 EBD Group이 주최하는 Biotech Showcase는 사모 및 마이크로 중형 생명공학 회사들이 자신의 혁신을 출품하고 투자자들과 연결하는 주요 투자자 회의로 기능합니다.
Azitra (NYSE American: AZTR), une société biopharmaceutique en phase clinique spécialisée dans la dermatologie de précision, a annoncé sa participation au Biotech Showcase 2025. L'événement se déroulera du 13 au 15 janvier 2025 à San Francisco, avec la présentation d'Azitra prévue pour le 13 janvier à 15h00 PT à l'Hilton San Francisco Union Square.
Le directeur des opérations, Travis Whitfill, dirigera la présentation, et l'équipe de direction de l'entreprise organisera des réunions individuelles avec des investisseurs inscrits et des partenaires potentiels. Ces réunions se concentreront sur la discussion de la stratégie commerciale d'Azitra, des plans de développement clinique, des succès récents et des jalons futurs.
Le Biotech Showcase, organisé par Demy-Colton et le EBD Group, sert de conférence phare pour les investisseurs, permettant aux entreprises biopharmaceutiques privées et de taille intermédiaire de présenter leurs innovations et de se connecter avec des investisseurs.
Azitra (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Dermatologie spezialisiert hat, hat seine Teilnahme an Biotech Showcase 2025 angekündigt. Die Veranstaltung findet vom 13. bis 15. Januar 2025 in San Francisco statt, wobei die Präsentation von Azitra für den 13. Januar um 15:00 Uhr PT im Hilton San Francisco Union Square geplant ist.
Der Chief Operating Officer Travis Whitfill wird die Präsentation leiten, und das Management-Team des Unternehmens wird persönliche Treffen mit registrierten Investoren und potenziellen Partnern durchführen. Diese Treffen werden sich auf die Diskussion über Azitras Geschäftsstrategie, klinische Entwicklungspläne, kürzliche Erfolge und zukünftige Meilensteine konzentrieren.
Der Biotech Showcase, organisiert von Demy-Colton und EBD Group, dient als führende Investorenkonferenz für private und mikro-mittlere Biotechnologieunternehmen, um ihre Innovationen vorzustellen und Verbindungen zu Investoren herzustellen.
- None.
- None.
Details of the presentation are as follows:
Event: | Biotech Showcase 2025 |
Date and Time: | January 13, 2025 at 3:00 p.m., PT |
Location: | Hilton San Francisco Union Square (Yosemite C) |
Participant: | Travis Whitfill, Chief Operating Officer |
Registration: |
During the conference, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Biotech Showcase, produced by Demy-Colton and EBD Group, is a premier investor conference committed to creating a platform for private and micro-mid-cap biotechnology companies. It offers companies a unique opportunity to showcase their innovations and engage directly with investors and other biopharmaceutical executives.
About Azitra, Inc.
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead product, ATR-12, is an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome is often fatal in infancy with those living beyond a year having profound lifelong challenges. ATR-12 is being evaluated in a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's next most advanced product, is being developed for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR-12, the filing of an IND application, and the presentation of data from our Phase 1b for ATR-04, the IND filing for ATR-01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial for ATR-12; we may experience delays in the initiation of our Phase 1/2 trial for ATR-04; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our prospectus dated July 23, 2024 filed with the SEC on July 25, 2024 in our most recent quarterly report on Form 10-Q filed with the SEC on November 12, 2024. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-to-present-at-biotech-showcase-2025-alongside-the-jp-morgan-annual-healthcare-conference-302337328.html
SOURCE Azitra, Inc.
FAQ
When and where is Azitra (AZTR) presenting at Biotech Showcase 2025?
What will Azitra (AZTR) discuss during their Biotech Showcase 2025 meetings?
Who will represent Azitra (AZTR) at the Biotech Showcase 2025 presentation?
What is the purpose of Azitra's (AZTR) participation in Biotech Showcase 2025?
What type of companies participate in Biotech Showcase 2025?
